Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction

International Journal of Molecular Sciences

Volumn 18, Issue 6, 2017, Pages

  Achari, Arunkumar E ^a   Jain, Sushil K ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

Adiponectin; Endothelial dysfunction; Obesity; Type 2 diabetes

Indexed keywords

ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; SYNAPTOPHYSIN; ADIPONECTIN; ADIPOQ PROTEIN, HUMAN;

DIABETES MELLITUS; DOWNSTREAM PROCESSING; ENDOTHELIAL DYSFUNCTION; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; OBESITY; PROTEIN EXPRESSION; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; VASCULAR ENDOTHELIUM; ANIMAL; CARDIOVASCULAR DISEASE; DRUG EFFECTS; ENDOTHELIUM; METABOLISM; MOLECULAR MODEL; MOLECULARLY TARGETED THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY;

ADIPONECTIN; ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM; HUMANS; INSULIN RESISTANCE; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; OBESITY; SIGNAL TRANSDUCTION;

EID: 85021065617     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18061321     Document Type: Review

References (129)

1. Ghoshal, K., Bhattacharyya, M. Adiponectin: Probe of the molecular paradigm associating diabetes and obesity. World J. Diabetes 2015, 6, 151-166.
2. Scherer, P.E., Williams, S., Fogliano, M., Baldini, G., Lodish, H.F. A novel serum protein similar to c1q, produced exclusively in adipocytes. J. Biol. Chem. 1995, 270, 26746-26749.
3. Maeda, K., Okubo, K., Shimomura, I., Funahashi, T., Matsuzawa, Y., Matsubara, K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apm1 (adiposemost abundant gene transcript 1). Biochem. Biophys. Res. Commun. 1996, 221, 286-289.
4. Nakano, Y., Tobe, T., Choi-Miura, N.-H., Mazda, T., Tomita, M. Isolation and characterization of gbp28, a novel gelatin-binding protein purified from human plasma. J. Biochem. 1996, 120, 803-812.
5. Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001, 7, 941-946.
6. Okamoto, Y., Kihara, S., Ouchi, N., Nishida, M., Arita, Y., Kumada, M., Ohashi, K., Sakai, N., Shimomura, I., Kobayashi, H. Adiponectin reduces atherosclerosis in apolipoprotein e-deficient mice. Circulation 2002, 106, 2767-2770.
7. Matsuda, M., Shimomura, I., Sata, M., Arita, Y., Nishida, M., Maeda, N., Kumada, M., Okamoto, Y., Nagaretani, H., Nishizawa, H. Role of adiponectin in preventing vascular stenosis the missing link of adipo-vascular axis. J. Biol. Chem. 2002, 277, 37487-37491.
8. Ahima, R.S., Flier, J.S. Adipose tissue as an endocrine organ. Trends Endocrinol. Metab. 2000, 11, 327-332.
9. Fantuzzi, G. Adipose tissue, adipokines, and inflammation. J. Allergy Clin. Immunol. 2005, 115, 911-919.
10. Hausman, G.J. The comparative anatomy of adipose tissue. In New Perspectives in Adipose Tissue: Structure, Function and Development, Wiley: Hoboken, NJ, USA, 1985, pp. 1-21.
11. Hu, E., Liang, P., Spiegelman, B.M. Adipoq is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 1996, 271, 10697-10703.
12. Díez, J.J., Iglesias, P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur. J. Endocrinol. 2003, 148, 293-300.
13. Berner, H.S., Lyngstadaas, S.P., Spahr, A., Monjo, M., Thommesen, L., Drevon, C.A., Syversen, U., Reseland, J.E. Adiponectin and its receptors are expressed in bone-forming cells. Bone 2004, 35, 842-849.
14. Yoda-Murakami, M., Taniguchi, M., Takahashi, K., Kawamata, S., Saito, K., Choi-Miura, N.-H., Tomita, M. Change in expression of gbp28/adiponectin in carbon tetrachloride-administrated mouse liver. Biochem. Biophys. Res. Commun. 2001, 285, 372-377.
15. Delaigle, A.L.M., Jonas, J.-C., Bauche, I.B., Cornu, O., Brichard, S.M. Induction of adiponectin in skeletal muscle by inflammatory cytokines: In vivo and in vitro studies. Endocrinology 2004, 145, 5589-5597.
16. Patel, J.V., Abraheem, A., Dotsenko, O., Creamer, J., Gunning, M., Hughes, E.A., Lip, G.Y.H. Circulating serum adiponectin levels in patients with coronary artery disease: Relationship to atherosclerotic burden and cardiac function. J. Intern. Med. 2008, 264, 593-598.
17. Caminos, J.E., Nogueiras, R.N., Gallego, R.A., Bravo, S., Tovar, S., Garcã-Caballero, T.S., Casanueva, F.F., Diéguez, C. Expression and regulation of adiponectin and receptor in human and rat placenta. J. Clin. Endocrinol. Metab. 2005, 90, 4276-4286.
18. Saito, K., Tobe, T., Minoshima, S., Asakawa, S., Sumiya, J., Yoda, M., Nakano, Y., Shimizu, N., Tomita, M. Organization of the gene for gelatin-binding protein (gbp28). Gene 1999, 229, 67-73.
19. Takahashi, M., Arita, Y., Yamagata, K., Matsukawa, Y., Okutomi, K., Horie, M., Shimomura, I., Hotta, K., Kuriyama, H., Kihara, S. Genomic structure and mutations in adipose-specific gene, adiponectin. Int. J. Obes. 2000, 24, 861-868.
20. Kissebah, A.H., Sonnenberg, G.E., Myklebust, J., Goldstein, M., Broman, K., James, R.G., Marks, J.A., Krakower, G.R., Jacob, H.J., Weber, J. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc. Natl. Acad. Sci. USA 2000, 97, 14478-14483.
21. Mori, Y., Otabe, S., Dina, C., Yasuda, K., Populaire, C.L., Lecoeur, C.C., Vatin, V., Durand, E., Hara, K., Okada, T. Genome-wide search for type 2 diabetes in japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate loci on 7p and 11p. Diabetes 2002, 51, 1247-1255.
22. Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999, 425, 560-564.
23. Hotta, K., Funahashi, T., Arita, Y., Takahashi, M., Matsuda, M., Okamoto, Y., Iwahashi, H., Kuriyama, H., Ouchi, N., Maeda, K. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 1595-1599.
24. Magkos, F., Sidossis, L.S. Recent advances in the measurement of adiponectin isoform distribution. Curr. Opin. Clin. Nutr. Metab. Care 2007, 10, 571-575.
25. Pajvani, U.B., Hawkins, M., Combs, T.P., Rajala, M.W., Doebber, T., Berger, J.P., Wagner, J.A., Wu, M., Knopps, A., Xiang, A.H. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J. Biol. Chem. 2004, 279, 12152-12162.
26. Fruebis, J., Tsao, T.-S., Javorschi, S., Ebbets-Reed, D., Erickson, M.R.S., Yen, F.T., Bihain, B.E., Lodish, H.F. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. USA 2001, 98, 2005-2010.
27. Wang, Z.V., Schraw, T.D., Kim, J.-Y., Khan, T., Rajala, M.W., Follenzi, A., Scherer, P.E. Secretion of the adipocyte-specific secretory protein adiponectin critically depends on thiol-mediated protein retention. Mol. Cell. Biol. 2007, 27, 3716-3731.
28. Qiang, L., Wang, H., Farmer, S.R. Adiponectin secretion is regulated by sirt1 and the endoplasmic reticulum oxidoreductase ero1-lα. Mol. Cell. Biol. 2007, 27, 4698-4707.
29. Liu, M., Zhou, L., Xu, A., Lam, K.S.L., Wetzel, M.D., Xiang, R., Zhang, J., Xin, X., Dong, L.Q., Liu, F. A disulfide-bond a oxidoreductase-like protein (dsba-l) regulates adiponectin multimerization. Proc. Natl. Acad. Sci. USA 2008, 105, 18302-18307.
30. Frizzell, N., Rajesh, M., Jepson, M.J., Nagai, R., Carson, J.A., Thorpe, S.R., Baynes, J.W. Succination of thiol groups in adipose tissue proteins in diabetes succination inhibits polymerization and secretion of adiponectin. J. Biol. Chem. 2009, 284, 25772-25781.
31. Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., Sugiyama, T., Miyagishi, M., Hara, K., Tsunoda, M. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423, 762-769.
32. Hug, C., Wang, J., Ahmad, N.S., Bogan, J.S., Tsao, T.-S., Lodish, H.F. T-cadherin is a receptor for hexameric and high-molecular-weight forms of acrp30/adiponectin. Proc. Natl. Acad. Sci. USA 2004, 101, 10308-10313.
33. Hebbard, L.W., Garlatti, M.L., Young, L.J.T., Cardiff, R.D., Oshima, R.G., Ranscht, B. T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Res. 2008, 68, 1407-1416.
34. Denzel, M.S., Scimia, M.-C., Zumstein, P.M., Walsh, K., Ruiz-Lozano, P., Ranscht, B. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J. Clin. Investig. 2010, 120, 4342-4352.
35. Parker-Duffen, J.L., Nakamura, K., Silver, M., Kikuchi, R., Tigges, U., Yoshida, S., Denzel, M.S., Ranscht, B., Walsh, K. T-cadherin is essential for adiponectin-mediated revascularization. J. Biol. Chem. 2013, 288, 24886-24897.
36. Miaczynska, M., Christoforidis, S., Giner, A., Shevchenko, A., Uttenweiler-Joseph, S., Habermann, B., Wilm, M., Parton, R.G., Zerial, M. Appl proteins link rab5 to nuclear signal transduction via an endosomal compartment. Cell 2004, 116, 445-456.
37. Gallop, J.L., McMahon, H.T. Biochemical Society Symposia. In Bar Domains and Membrane Curvature: Bringing Your Curves to the Bar, Portland Press Limited: London, UK, 2005, pp. 223-231.
38. Habermann, B. The BAR-domain family of proteins: A case of bending and binding? EMBO Rep. 2004, 5, 250-255.
39. Lee, M.C.S., Schekman, R. Bar domains go on a bender. Science 2004, 303, 479-480.
40. Ren, G., Vajjhala, P., Lee, J.S., Winsor, B., Munn, A.L. The bar domain proteins: Molding membranes in fission, fusion, and phagy. Microbiol. Mol. Biol. Rev. 2006, 70, 37-120.
41. Dawson, J.C., Legg, J.A., Machesky, L.M. Bar domain proteins: A role in tubulation, scission and actin assembly in clathrin-mediated endocytosis. Trends Cell Biol. 2006, 16, 493-498.
42. Peter, B.J., Kent, H.M., Mills, I.G., Vallis, Y., Butler, P.J.G., Evans, P.R., McMahon, H.T. Bar domains as sensors of membrane curvature: The amphiphysin bar structure. Science 2004, 303, 495-499.
43. Mao, X., Kikani, C.K., Riojas, R.A., Langlais, P., Wang, L., Ramos, F.J., Fang, Q., Christ-Roberts, C.Y., Hong, J.Y., Kim, R.-Y. Appl1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat. Cell Biol. 2006, 8, 516-523.
44. Nechamen, C.A., Thomas, R.M., Dias, J.A. Appl1, appl2, akt2 and foxo1a interact with fshr in a potential signaling complex. Mol. Cell. Endocrinol. 2007, 260, 93-99.
45. Berg, A.H., Combs, T.P., Du, X., Brownlee, M., Scherer, P.E. The adipocyte-secreted protein acrp30 enhances hepatic insulin action. Nat. Med. 2001, 7, 947-953.
46. Deepa, S.S., Zhou, L., Ryu, J., Wang, C., Mao, X., Li, C., Zhang, N., Musi, N., DeFronzo, R.A., Liu, F. Appl1 mediates adiponectin-induced lkb1 cytosolic localization through the PP2A-PKCzeta signaling pathway. Mol. Endocrinol. 2011, 25, 1773-1785.
47. Zhao, L., Fu, Z., Wu, J., Aylor, K.W., Barrett, E.J., Cao, W., Liu, Z. Globular adiponectin ameliorates metabolic insulin resistance via AMPK-mediated restoration of microvascular insulin responses. J. Physiol. 2015, 593, 4067-4079.
48. Xin, X., Zhou, L., Reyes, C.M., Liu, F., Dong, L.Q. Appl1 mediates adiponectin-stimulated p38 mapk activation by scaffolding the tak1-mkk3-p38 mapk pathway. Am. J. Physiol. Endocrinol. Metab. 2011, 300, E103-E110.
49. Cheng, K.K.Y., Lam, K.S.L., Wang, Y., Huang, Y., Carling, D., Wu, D., Wong, C., Xu, A. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by appl1 in endothelial cells. Diabetes 2007, 56, 1387-1394.
50. Fang, X., Palanivel, R., Cresser, J., Schram, K., Ganguly, R., Thong, F.S.L., Tuinei, J., Xu, A., Abel, E.D., Sweeney, G. An appl1-ampk signaling axis mediates beneficial metabolic effects of adiponectin in the heart. Am. J. Physiol. Endocrinol. Metab. 2010, 299, E721-E729.
51. Inoki, K., Zhu, T., Guan, K.-L. Tsc2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115, 577-590.
52. Inoki, K., Li, Y., Zhu, T., Wu, J., Guan, K.-L. Tsc2 is phosphorylated and inhibited by akt and suppresses mtor signalling. Nat. Cell Biol. 2002, 4, 648-657.
53. Kramer, H.F., Witczak, C.A., Fujii, N., Jessen, N., Taylor, E.B., Arnolds, D.E., Sakamoto, K., Hirshman, M.F., Goodyear, L.J. Distinct signals regulate as160 phosphorylation in response to insulin, aicar, and contraction in mouse skeletal muscle. Diabetes 2006, 55, 2067-2076.
54. Treebak, J.T., Glund, S., Deshmukh, A., Klein, D.K., Long, Y.C., Jensen, T.E., Jãrgensen, S.B., Viollet, B., Andersson, L., Neumann, D. Ampk-mediated as160 phosphorylation in skeletal muscle is dependent on ampk catalytic and regulatory subunits. Diabetes 2006, 55, 2051-2058.
55. Lochhead, P.A., Salt, I.P., Walker, K.S., Hardie, D.G., Sutherland, C. 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes pepck and glucose-6-phosphatase. Diabetes 2000, 49, 896-903.
56. Liao, Y., Takashima, S., Maeda, N., Ouchi, N., Komamura, K., Shimomura, I., Hori, M., Matsuzawa, Y., Funahashi, T., Kitakaze, M. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc. Res. 2005, 67, 705-713.
57. Ye, J.-M., Doyle, P.J., Iglesias, M.A., Watson, D.G., Cooney, G.J., Kraegen, E.W. Peroxisome proliferator-activated receptor (PPAR)-α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats. Diabetes 2001, 50, 411-417.
58. Yamauchi, T., Kamon, J., Minokoshi, Y.A., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating amp-activated protein kinase. Nat. Med. 2002, 8, 1288-1295.
59. Ceddia, R.B., Somwar, R., Maida, A., Fang, X., Bikopoulos, G., Sweeney, G. Globular adiponectin increases glut4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia 2005, 48, 132-139.
60. Holland, W.L., Brozinick, J.T., Wang, L.-P., Hawkins, E.D., Sargent, K.M., Liu, Y., Narra, K., Hoehn, K.L., Knotts, T.A., Siesky, A. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 2007, 5, 167-179.
61. Summers, S.A. Ceramides in insulin resistance and lipotoxicity. Prog. Lipid Res. 2006, 45, 42-72.
62. Ono, K., Han, J. The p38 signal transduction pathway activation and function. Cell. Signal. 2000, 12, 1-13.
63. Yoon, M.J., Lee, G.Y., Chung, J.-J., Ahn, Y.H., Hong, S.H., Kim, J.B. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of amp-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor α. Diabetes 2006, 55, 2562-2570.
64. Pelletier, A.L., Joly, E.R., Prentki, M., Coderre, L. Adenosine 50-monophosphate-activated protein kinase and p38 mitogen-activated protein kinase participate in the stimulation of glucose uptake by dinitrophenol in adult cardiomyocytes. Endocrinology 2005, 146, 2285-2294.
65. Ross, R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340, 115-126.
66. Sattar, N., Wannamethee, G., Sarwar, N., Tchernova, J., Cherry, L., Wallace, A.M., Danesh, J., Whincup, P.H. Adiponectin and coronary heart disease. Circulation 2006, 114, 623-629.
67. Iwashima, Y., Katsuya, T., Ishikawa, K., Ouchi, N., Ohishi, M., Sugimoto, K., Fu, Y., Motone, M., Yamamoto, K., Matsuo, A. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004, 43, 1318-1323.
68. Lam, K.S.L., Xu, A. Adiponectin: Protection of the endothelium. Curr. Diabetes Rep. 2005, 5, 254-259.
69. Shibata, R., Ouchi, N., Kihara, S., Sato, K., Funahashi, T., Walsh, K. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J. Biol. Chem. 2004, 279, 28670-28674.
70. Nishimura, M., Izumiya, Y., Higuchi, A., Shibata, R., Qiu, J., Kudo, C., Shin, H.K., Moskowitz, M.A., Ouchi, N. Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase-dependent mechanisms. Circulation 2008, 117, 216-223.
71. Ohashi, K., Kihara, S., Ouchi, N., Kumada, M., Fujita, K., Hiuge, A., Hibuse, T., Ryo, M., Nishizawa, H., Maeda, N. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006, 47, 1108-1116.
72. Okamoto, Y., Folco, E.J., Minami, M., Wara, A.K., Feinberg, M.W., Sukhova, G.K., Colvin, R.A., Kihara, S., Funahashi, T., Luster, A.D. Adiponectin inhibits the production of cxc receptor 3 chemokine ligands in macrophages and reduces t-lymphocyte recruitment in atherogenesis. Circ. Res. 2008, 102, 218-225.
73. Nawrocki, A.R., Hofmann, S.M., Teupser, D., Basford, J.E., Durand, J.L., Jelicks, L.A., Woo, C.W., Kuriakose, G., Factor, S.M., Tanowitz, H.B. Lack of association between adiponectin levels and atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 1159-1165.
74. Ouchi, N., Kobayashi, H., Kihara, S., Kumada, M., Sato, K., Inoue, T., Funahashi, T., Walsh, K. Adiponectin stimulates angiogenesis by promoting cross-talk between amp-activated protein kinase and akt signaling in endothelial cells. J. Biol. Chem. 2004, 279, 1304-1309.
75. Kobayashi, H., Ouchi, N., Kihara, S., Walsh, K., Kumada, M., Abe, Y., Funahashi, T., Matsuzawa, Y. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ. Res. 2004, 94, e27-e31.
76. Kobashi, C., Urakaze, M., Kishida, M., Kibayashi, E., Kobayashi, H., Kihara, S., Funahashi, T., Takata, M., Temaru, R., Sato, A. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ. Res. 2005, 97, 1245-1252.
77. Ouchi, N., Kihara, S., Arita, Y., Okamoto, Y., Maeda, K., Kuriyama, H., Hotta, K., Nishida, M., Takahashi, M., Muraguchi, M. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a camp-dependent pathway. Circulation 2000, 102, 1296-1301.
78. Ohashi, K., Ouchi, N., Sato, K., Higuchi, A., Ishikawa, T.-O., Herschman, H.R., Kihara, S., Walsh, K. Adiponectin promotes revascularization of ischemic muscle through a cyclooxygenase 2-dependent mechanism. Mol. Cell. Biol. 2009, 29, 3487-3499.
79. Ikeda, Y., Ohashi, K., Shibata, R., Pimentel, D.R., Kihara, S., Ouchi, N., Walsh, K. Cyclooxygenase-2 induction by adiponectin is regulated by a sphingosine kinase-1 dependent mechanism in cardiac myocytes. FEBS Lett. 2008, 582, 1147-1150.
80. Sam, F., Duhaney, T.-A.S., Sato, K., Wilson, R.M., Ohashi, K., Sono-Romanelli, S., Higuchi, A., De Silva, D.S., Qin, F., Walsh, K. Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure. Endocrinology 2010, 151, 322-331.
81. Shibata, R., Izumiya, Y., Sato, K., Papanicolaou, K., Kihara, S., Colucci, W.S., Sam, F., Ouchi, N., Walsh, K. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J. Mol. Cell. Cardiol. 2007, 42, 1065-1074.
82. Yamauchi, T., Nio, Y., Maki, T., Kobayashi, M., Takazawa, T., Iwabu, M., Okada-Iwabu, M., Kawamoto, S., Kubota, N., Kubota, T. Targeted disruption of adipor1 and adipor2 causes abrogation of adiponectin binding and metabolic actions. Nat. Med. 2007, 13, 332-339.
83. Wyder, L., Vitaliti, A., Schneider, H., Hebbard, L.W., Moritz, D.R., Wittmer, M., Ajmo, M., Klemenz, R. Increased expression of h/t-cadherin in tumor-penetrating blood vessels. Cancer Res. 2000, 60, 4682-4688.
84. Tkachuk, V.A., Bochkov, V.N., Philippova, M.P., Stambolsky, D.V., Kuzmenko, E.S., Sidorova, M.V., Molokoedov, A.S., Spirov, V.G., Resink, T.J. Identification of an atypical lipoprotein-binding protein from human aortic smooth muscle as t-cadherin. FEBS Lett. 1998, 421, 208-212.
85. Ivanov, D., Philippova, M., Antropova, J., Gubaeva, F., Iljinskaya, O., Tararak, E., Bochkov, V., Erne, P., Resink, T., Tkachuk, V. Expression of cell adhesion molecule t-cadherin in the human vasculature. Histochem. Cell Biol. 2001, 115, 231-242.
86. Moschen, A.R., Wieser, V., Tilg, H. Adiponectin: Key player in the adipose tissue-liver crosstalk. Curr. Med. Chem. 2012, 19, 5467-5473.
87. Whitehead, J.P., Richards, A.A., Hickman, I.J., Macdonald, G.A., Prins, J.B. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes. Metab. 2006, 8, 264-280.
88. Sowers, J.R. Endocrine functions of adipose tissue: Focus on adiponectin. Clin. Cornerstone 2008, 9, 32-40.
89. Fu, Y., Luo, N., Klein, R.L., Garvey, W.T. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J. Lipid Res. 2005, 46, 1369-1379.
90. Kim, J.-Y., Van De Wall, E., Laplante, M., Azzara, A., Trujillo, M.E., Hofmann, S.M., Schraw, T., Durand, J.L., Li, H., Li, G. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Investig. 2007, 117, 2621-2637.
91. Combs, T.P., Pajvani, U.B., Berg, A.H., Lin, Y., Jelicks, L.A., Laplante, M., Nawrocki, A.R., Rajala, M.W., Parlow, A.F., Cheeseboro, L. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 2004, 145, 367-383.
92. Bauer, S., Weigert, J., Neumeier, M., Wanninger, J., Schãffler, A., Luchner, A., Schnitzbauer, A.A., Aslanidis, C., Buechler, C. Low-abundant adiponectin receptors in visceral adipose tissue of humans and rats are further reduced in diabetic animals. Arch. Med. Res. 2010, 41, 75-82.
93. Nordlie, R.C., Foster, J.D., Lange, A.J. Regulation of glucose production by the liver. Ann. Rev. Nutr. 1999, 19, 379-406.
94. Combs, T.P., Berg, A.H., Obici, S., Scherer, P.E., Rossetti, L. Endogenous glucose production is inhibited by the adipose-derived protein ACRP30. J. Clin. Investig. 2001, 108, 1875-1881.
95. Pajvani, U.B., Du, X., Combs, T.P., Berg, A.H., Rajala, M.W., Schulthess, T., Engel, J.R., Brownlee, M., Scherer, P.E. Structure-function studies of the adipocyte-secreted hormone acrp30/adiponectin implications for metabolic regulation and bioactivity. J. Biol. Chem. 2003, 278, 9073-9085.
96. Nawrocki, A.R., Rajala, M.W., Tomas, E., Pajvani, U.B., Saha, A.K., Trumbauer, M.E., Pang, Z., Chen, A.S., Ruderman, N.B., Chen, H. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor Î3 agonists. J. Biol. Chem. 2006, 281, 2654-2660.
97. Xu, A., Wang, Y., Keshaw, H., Xu, L.Y., Lam, K.S.L., Cooper, G.J.S. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Investig. 2003, 112, 91-100.
98. Brooks, N.L., Trent, C.M., Raetzsch, C.F., Flurkey, K., Boysen, G., Perfetti, M.T., Jeong, Y.-C., Klebanov, S., Patel, K.B., Khodush, V.R. Low utilization of circulating glucose after food withdrawal in snell dwarf mice. J. Biol. Chem. 2007, 282, 35069-35077.
99. Towler, M.C., Hardie, D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ. Res. 2007, 100, 328-341.
100. Maeda, K., Ishihara, K., Miyake, K., Kaji, Y., Kawamitsu, H., Fujii, M., Sugimura, K., Ohara, T. Inverse correlation between serum adiponectin concentration and hepatic lipid content in japanese with type 2 diabetes. Metabolism 2005, 54, 775-780.
101. Vuppalanchi, R., Marri, S., Kolwankar, D., Considine, R.V., Chalasani, N. Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J. Clin. Gastroenterol. 2005, 39, 237-242.
102. Kaser, S., Moschen, A., Cayon, A., Kaser, A., Crespo, J., Pons-Romero, F., Ebenbichler, C.F., Patsch, J.R., Tilg, H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005, 54, 117-121.
103. Sanyal, A.J., Campbell-Sargent, C., Mirshahi, F., Rizzo, W.B., Contos, M.J., Sterling, R.K., Luketic, V.A., Shiffman, M.L., Clore, J.N. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120, 1183-1192.
104. Zhou, M., Xu, A., Tam, P.K.H., Lam, K.S.L., Chan, L., Hoo, R.L.C., Liu, J., Chow, K.H.M., Wang, Y. Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury. Hepatology 2008, 48, 1087-1096.
105. Yamauchi, T., Kamon, J., Waki, H., Murakami, K., Motojima, K., Komeda, K., Ide, T., Kubota, N., Terauchi, Y., Tobe, K. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor î3 (pparî3) deficiency and pparî3 agonist improve insulin resistance. J. Biol. Chem. 2001, 276, 41245-41254.
106. Combs, T.P., Wagner, J.A., Berger, J., Doebber, T., Wang, W.-J., Zhang, B.B., Tanen, M., Berg, A.H., Oorahilly, S., Savage, D.B. Induction of adipocyte complement-related protein of 30 kilodaltons by pparî3 agonists: A potential mechanism of insulin sensitization. Endocrinology 2002, 143, 998-1007.
107. Phillips, S.A., Ciaraldi, T.P., Kong, A.P.S., Bandukwala, R., Aroda, V., Carter, L., Baxi, S., Mudaliar, S.R., Henry, R.R. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003, 52, 667-674.
108. Kubota, N., Terauchi, Y., Kubota, T., Kumagai, H., Itoh, S., Satoh, H., Yano, W., Ogata, H., Tokuyama, K., Takamoto, I. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and-independent pathways. J. Biol. Chem. 2006, 281, 8748-8755.
109. Xu, A., Wang, H., Hoo, R.L.C., Sweeney, G., Vanhoutte, P.M., Wang, Y., Wu, D., Chu, W., Qin, G., Lam, K.S.L. Selective elevation of adiponectin production by the natural compounds derived from a medicinal herb alleviates insulin resistance and glucose intolerance in obese mice. Endocrinology 2009, 150, 625-633.
110. Mohammadi, A., Gholamhoseinian, A., Fallah, H. Zataria multiflora increases insulin sensitivity and pparî3 gene expression in high fructose fed insulin resistant rats. Iran. J. Basic Med. Sci. 2014, 17, 263-270.
111. Gómez-Arbeláez, D., Lahera, V., Oubiña, P., Valero-Muñoz, M., de las Heras, N., Rodríguez, Y., García, R.G., Camacho, P.A., López-Jaramillo, P. Aged garlic extract improves adiponectin levels in subjects with metabolic syndrome: A double-blind, placebo-controlled, randomized, crossover study. Med. Inflamm. 2013, 2013.
112. Li, M., Kim, D.H., Tsenovoy, P.L., Peterson, S.J., Rezzani, R., Rodella, L.F., Aronow, W.S., Ikehara, S., Abraham, N.G. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes 2008, 57, 1526-1535.
113. Achari, A.E., Jain, S.K. L-cysteine supplementation increases adiponectin synthesis and secretion, and glut4 and glucose utilization by upregulating disulfide bond a-like protein expression mediated by mcp-1 inhibition in 3t3-l1 adipocytes exposed to high glucose. Mol. Cell. Biochem. 2016, 414, 105-113.
114. Burlet, E., Jain, S.K. Manganese supplementation increases adiponectin and lowers icam-1 and creatinine blood levels in zucker type 2 diabetic rats, and downregulates icam-1 by upregulating adiponectin multimerization protein (DSBA-l) in endothelial cells. Mol. Cell. Biochem. 2017, 429, 1-10.
115. Decochez, K., Rippley, R.K., Miller, J.L., De Smet, M., Yan, K.X., Matthijs, Z., Riffel, K.A., Song, H., Zhu, H., Maynor, H.O. A dual ppar α/γagonist increases adiponectin and improves plasma lipid profiles in healthy subjects. Drugs R&D 2006, 7, 99-110.
116. Furuhashi, M., Ura, N., Higashiura, K., Murakami, H., Tanaka, M., Moniwa, N., Yoshida, D., Shimamoto, K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003, 42, 76-81.
117. Saunders, T.J., Davidson, L.E., Janiszewski, P.M., Després, J.-P., Hudson, R., Ross, R. Associations of the limb fat to trunk fat ratio with markers of cardiometabolic risk in elderly men and women. J. Gerontol. A Biol. Sci. Med. Sci. 2009, 64, 1066-1070.
118. Gavrila, A., Chan, J.L., Yiannakouris, N., Kontogianni, M., Miller, L.C., Orlova, C., Mantzoros, C.S. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: Cross-sectional and interventional studies. J. Clin. Endocrinol. Metab. 2003, 88, 4823-4831.
119. Jurimae, J., Hofmann, P., Jurimae, T., Mãestu, J., Purge, P., Wonisch, M., Pokan, R., Von Duvillard, S.P. Plasma adiponectin response to sculling exercise at individual anaerobic threshold in college level male rowers. Int. J. Sports Med. 2006, 27, 272-277.
120. Jürimäe, J., Purge, P., Jürimäe, T. Adiponectin is altered after maximal exercise in highly trained male rowers. Eur. J. Appl. Physiol. 2005, 93, 502-505.
121. Kriketos, A.D., Gan, S.K., Poynten, A.M., Furler, S.M., Chisholm, D.J., Campbell, L.V. Exercise increases adiponectin levels and insulin sensitivity in humans. Diabetes Care 2004, 27, 629-630.
122. Numao, S., Katayama, Y., Hayashi, Y., Matsuo, T., Tanaka, K. Influence of acute aerobic exercise on adiponectin oligomer concentrations in middle-aged abdominally obese men. Metabolism 2011, 60, 186-194.
123. Hernandez, A.V., Usmani, A., Rajamanickam, A., Moheet, A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus. Am. J. Cardiovasc. Drugs 2011, 11, 115-128.
124. Aronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J.W., Mathisen, A.L., Schneider, R.L. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study. The pioglitazone 001 study group. Diabetes Care 2000, 23, 1605-1611.
125. Billington, E.O., Grey, A., Bolland, M.J. The Effect of Thiazolidinediones on Bone Mineral Density and Bone Turnover: Systematic Review and Meta-Analysis, Springer: New York, NY, USA, 2015.
126. Vestergaard, P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—A meta-analysis. Osteoporos. Int. 2007, 18, 427-444.
127. Lewis, J.D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W.B., Quesenberry, C.P., Vaughn, D.J., Nessel, L., Selby, J., Strom, B.L. Risk of bladder cancer among diabetic patients treated with pioglitazone. Diabetes Care 2011, 34, 916-922.
128. Fonseca, V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am. J. Med. 2003, 115, 42-48.
129. Ferris, F.L., Patz, A. Macular EDEMA. A complication of diabetic retinopathy. Surv. Ophthalmol. 1984, 28, 452-461.